drugset / Trial / NCT05099445
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.
Timeline
- Start
- 2021-12-14
- Primary completion
- 2023-02-19
- Completion
- 2023-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZILURGISERTIB | Small molecule | 200 mg | Oral |